Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 years old~* Diagnosed with type 2 diabetes~* Body mass index (BMI) ≤ 45 kg/m2~* HbA1c between 7 and 10% (inclusive) at screening~* FPG \<250 mg/dL at screening for subjects not treated with oral anti-diabetic therapies or FPG \<240 mg/dL at screening for subjects treated with anti-diabetic therapies~* Diabetes currently treated with diet and exercise only or diet and exercise along with one approved oral anti-diabetic agent~* If taking anti-diabetic medication, dose and regimen must be stable for past 3 months~* If taking anti-hypertensive medication, dose and regimen must be stable for past 3 months~* If taking lipid modifying therapy, dose and regimen must be stable for past 3 months~* Blood glucose \<250 mg/dL based on finger stick blood glucose for all subjects at randomization~Exclusion Criteria:~* Hemoglobinopathy that affects HbA1c measurement~* Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor based therapy)~* Genitourinary tract infection within 6 weeks of screening~* Greater than 2 episodes of genitourinary tract infection in the past year~* History of kidney stones, bladder malfunction or other significant risk factor for urinary tract infections~* eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), \< 50 mL/min/1.73 m2~* Abnormal tests of liver function ALT, AST or bilirubin ≥ 3x ULN~* Diagnosis of retinopathy or significant nephropathy (eGFR \< 50 mL/min/1.73 m2~* Uncontrolled hypertension (systolic blood pressure \>160 or diastolic blood pressure \>95)~* Not willing to use effective birth control, if female with child-bearing potential~* Life expectancy \< 2 years~* New York Heart Association (NYHA) Class 4 heart failure~* Sera positive of HCV, HIV, or positive on drug screen~* Currently participating in another interventional trial~* Previous treatment with EGT0001442 or EGT0001474~* Not able to comply with the study scheduled visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EGT0001442 (Type: EXPERIMENTAL): EGT0001442 capsule, 20 mg, daily, 96 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).